MARINUS PHARMACEUTICALS INC's ticker is MRNS and the CUSIP is 56854Q101. A total of 60 filers reported holding MARINUS PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 1.20 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2020 | $96,000 | -38.9% | 37,719 | -48.2% | 0.14% | +1700.0% |
Q4 2019 | $157,000 | +23.6% | 72,885 | -11.3% | 0.01% | +33.3% |
Q3 2019 | $127,000 | +8.5% | 82,170 | +192.4% | 0.01% | -14.3% |
Q2 2019 | $117,000 | -45.6% | 28,103 | -45.4% | 0.01% | -46.2% |
Q1 2019 | $215,000 | +211.6% | 51,453 | +114.4% | 0.01% | +225.0% |
Q4 2018 | $69,000 | -58.7% | 24,001 | -45.2% | 0.00% | -42.9% |
Q1 2018 | $167,000 | -83.9% | 43,828 | -65.5% | 0.01% | -84.8% |
Q4 2017 | $1,035,000 | +1468.2% | 126,952 | +160.9% | 0.05% | +1433.3% |
Q2 2017 | $66,000 | +4.8% | 48,658 | +36.3% | 0.00% | 0.0% |
Q1 2017 | $63,000 | +293.8% | 35,701 | +112.1% | 0.00% | +200.0% |
Q4 2016 | $16,000 | -77.5% | 16,830 | -57.0% | 0.00% | -95.7% |
Q3 2016 | $71,000 | -62.6% | 39,100 | +56.6% | 0.02% | +155.6% |
Q4 2015 | $190,000 | +12.4% | 24,969 | +22.9% | 0.01% | +50.0% |
Q3 2015 | $169,000 | -12.0% | 20,323 | +22.5% | 0.01% | 0.0% |
Q2 2015 | $192,000 | – | 16,595 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Bain Capital Life Sciences Investors, LLC | 5,042,735 | $14,473,000 | 4.95% |
VHCP Management III, LLC | 1,258,964 | $3,613,000 | 2.63% |
Granite Point Capital Management, L.P. | 2,659,367 | $7,632,000 | 1.54% |
Granite Point Capital Management, L.P. | 1,600,000 | $4,592,000 | 0.93% |
VHCP Management II, LLC | 743,876 | $2,135,000 | 0.92% |
Monashee Investment Management LLC | 250,000 | $718,000 | 0.49% |
683 Capital Management, LLC | 1,350,000 | $3,875,000 | 0.24% |
CAXTON CORP | 61,443 | $176,000 | 0.21% |
Tekla Capital Management LLC | 755,776 | $2,169,000 | 0.09% |
Fosun International Ltd | 491,997 | $1,378,000 | 0.08% |